Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials
NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) reported its full-year 2025 financial results and said it is advancing two pivotal clinical trials for therapies targeting hypertension and …
Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials Read More